In HGT-MLD-071, all patients in the 10 mg dose cohort who experienced disease progression, as determined by the Investigator, increased to the 30 mg dose after agreement by the Medical Monitor. Based on the interim analysis results from HGT-MLD-070 (Cohorts 1-3), the dose of HGT-1110 will be increased to 100 mg for all patients in HGT-MLD-071 after all necessary approvals were obtained.